SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing RRP treatment has put Precigens PAPZIMEOS in focus, with traders debating whether the entrant will threaten its sales. Some see a serious competitive risk, while others argue Precigens first-mover position and Inovios accelerated-approval and commercialization hurdles limit the near-term threat.

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

Energy Transfers strong quarterly results and upbeat outlook are driving discussion, with traders focused on growing natural-gas demand from data centers and new pipeline capacity. Many see the unit price as lagging the fundamentals, while others emphasize the steady distribution and the stocks typically slow price moves.

Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Energy Storage, Specialties, and Ketjen. The Energy Storage segment develops and manufactures a broad range of basic lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride. The Specialties segment focuses on optimizing a portfolio of bromine and specialized lithium solutions. The Ketjen segment consists of clean fuels technologies, fluidized catalytic cracking catalysts and additives, and performance catalyst solutions, which is primarily composed of organometallics and curatives. The company was founded in 1993 and is headquartered in Charlotte, NC.

Albemarle Corp.

Albemarle Corp

Renewed weakness in lithium prices and futures is weighing on Albemarle, with traders also watching upcoming earnings and guidance for signs of where the downturn may bottom. The community is split between expecting further declines and waiting to buy lower, and viewing the selloff as an opportunity based on longer-term battery demand.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is drawing attention as its shares slide toward reported NAV, with traders debating whether its premium is unwinding and criticizing the funds management and dilution. Anthropic exposure and a potential IPO remain hoped-for catalysts, but many traders are bearish after the weak price action.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare reimbursement could decline sharply after the first quarter of 2027 has fueled concern about pricing and CorMedixs largest revenue driver, amid a steep selloff. Traders disagree over the impact: some view DaVitas estimates as preliminary and not company revenue guidance, while others fear sustained reimbursement pressure.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys earnings and improving parks and streaming performance are supporting a bullish conversation, alongside traders watching for a technical breakout. Others remain skeptical, citing the stocks long-running stagnation and resistance near recent levels.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

A newly disclosed convertible-note financing and proposed increase in authorized shares have put dilution at the center of the discussion, with traders worried that price-linked conversions could add selling pressure and further erode confidence in management. Some holders argue the funding is needed to advance data-center projects and point to AI infrastructure demand, while others say execution and financing risks outweigh that potential.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

RIG is drawing attention around progress toward completing its Valaris merger, alongside bullish options activity and optimism about rising offshore dayrates and contract backlog. Traders see potential for a breakout or short squeeze, while others worry about merger-related dilution, debt, and a tendency for rallies to fade.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

A sharp selloff and put-heavy options flow have focused attention on AEHR, with traders debating whether the decline reflects stretched valuation and fading momentum or an opportunity ahead of earnings. Bulls are looking for confirmation of the companys AI-related growth outlook and additional orders, while bears remain concerned about execution and the lack of fresh customer wins.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Targets quarterly earnings beat and higher full-year outlook, supported by improving traffic and sales, have renewed attention on its turnaround. Traders are upbeat about the operational momentum but question how durable the gains are because tariff refunds boosted reported results, and some point to slowing comparable-sales growth and a sell-the-news pullback.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Iovances updated IOV-LUN-202 non-small-cell lung cancer results and shift toward biomarker-selected development are driving attention: the broad-population data, immature durability and later filing timeline disappointed traders, while the strong response in a narrower subgroup has some investors arguing the selloff overstates the setback. The community also criticizes the confusing rollout and debates regulatory prospects and market size, with bullish posters pointing to the planned prospective study and the continuing melanoma business.

SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3

The decline appears tied to Iovances updated Phase 2 lung-cancer data: lifileucels response rate was 24.6% among 69 patients, while the 59.1% rate came from a retrospective biomarker-selected subgroup. Concerns about the broader results, immature durability data and a 2027 filing timeline were compounded by confusion around managements presentation.

GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth

Gilead tops Q3 earnings and revenue estimates as HIV sales, Trodelvy and Livdelzi drive growth, prompting an increase in 2026 product sales guidance.

INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance 

Insmed's third-quarter revenues surge 268%, fueled by strong Brinsupri sales, prompting a 15% stock rally and higher 2026 sales guidance.

Equity

Virginia Retirement Systems raised its stakes in all three stocks, with combined holdings worth nearly $3 million at September-end.

Dow, S&P 500, Nasdaq Futures Fall As Weak Tech Earnings Trigger Selloff: INTC, IOVA, SLS, AMZN Stocks In Focus

Markets are headed for a mixed close in October, with the Nasdaq likely to end lower, while the Dow and S&P 500 are headed to close in the green.

Illumina (ILMN) Q3 Earnings Beat Estimates

Illumina (ILMN) delivered earnings and revenue surprises of +5.88% and -0.76%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Amarin's Q3 Earnings Beat Estimates, Revenues Miss Mark

AMRN's Q3 2026 earnings surpass estimates despite declining revenues. Global Vascepa/Vazkepa demand grows 55% and cash reserves increase.

IOVA Stock Heads For Worst Day In Over 17 Months, Retail Says ‘Selling Is Not Done’ – What’s Driving The Fall?

Iovance reported updated results from its Phase 2 IOV-LUN-202 trial evaluating Lifileucel in patients with metastatic non-squamous non-small-cell lung cancer.


BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises

Bausch Health shares jump 9% as Q3 earnings top estimates, driven by Xifaxan-led Salix growth, improved profitability and raised 2026 guidance.

Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?

RXRX heads into Q3 earnings with key collaboration milestones, advancing clinical programs and upcoming pipeline updates that could shape its outlook.

Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>China Universal and Mirae added to IOVA and IBRX, while other institutions cut positions.</li><li>IOVA plunged after updated Lifileucel lung-cancer data, despite stronger responses in a selected subgroup.</li><li>Sellas’ Regal trial reached its 80th event, triggering final analysis, with results expected this quarter.</li></ul><p>Sellas Life Sciences (SLS), Iovance Biotherapeutics (IOVA) and ImmunityBio (IBRX) are closing out a difficult October, even as recent filings reveal that Virginia Retirement&nbsp;System entered the month with larger stakes in all three companies.</p><p>So far this month,&nbsp;<a href="https://stocktwits.com/symbol/SLS">SLS</a> has fallen 18%,&nbsp;<a href="https://stocktwits.com/symbol/IOVA">IOVA</a> is down 35% and&nbsp;<a href="https://stocktwits.com/symbol/IBRX">IBRX</a> has lost 7%. All three lagged the&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF (XBI)</a>, which recovered from earlier weakness to trade nearly flat for the month.&nbsp;</p><h2 class="st-heading-2"><strong>Who Added And Who Cut Their Holdings In SLS, IBRX, And IOVA</strong></h2><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col><col></colgroup><tbody><tr><td>Stock</td><td>Shares held as of Sept.30</td><td>Shares added</td><td>Increase</td></tr><tr><td>SLS</td><td>26,500</td><td>9,100</td><td>52%</td></tr><tr><td>IOVA</td><td>131,450</td><td>23,400</td><td>22%</td></tr><tr><td>IBRX</td><td>76,000</td><td>1,500</td><td>2%</td></tr></tbody></table></figure></div><p>The pension investor’s three positions were worth nearly $3 million combined at quarter-end.</p><p>Meanwhile, other institutions took different routes: China Universal and Mirae Asset each raised their IOVA and IBRX holdings by 16%, according to Fiscal.ai. Raiffeisen cut its IOVA stake by 26% to 280,000 shares, while Leonteq reduced its holding by 60% to 60,000 shares.</p><p>In SLS, Daiwa nearly exited, cutting its position by 99.9% to 100 shares. Wyoming reduced its stake by 92% to 1,635 shares, while SJS Investment Consulting held steady at 40,000 shares. Parkside’s eye-catching 32,650% increase came from a tiny base: its holding rose from two shares to 655.</p><h2 class="st-heading-2"><strong>Lung-Cancer Data Tests IOVA Bulls</strong></h2><p>Iovance plunged 36% to $9.56 on Thursday after updated Lifileucel lung-cancer data showed a 24.6% response rate in 69 patients, versus 25.6% previously reported in 39. Two responses await confirmation.</p><p>A retrospectively selected subgroup of 22 patients achieved a 59.1% response rate. “In the enriched subgroup, nearly six in ten patients responded, including two complete responses,” interim CEO Frederick Vogt said. Iovance plans to begin enrolling a prospective biomarker-selected cohort in November and targets a 2027 FDA submission for the broader lung-cancer program.</p><p>Lifileucel is already sold as Amtagvi for advanced melanoma. Demand for Amtagvi and Proleukin drove September’s increase in 2026 revenue guidance to $410 million to $420 million from a range of $350 million to $370 million.&nbsp;</p><h2 class="st-heading-2"><strong>A Key Trial Milestone Fails To Lift SLS</strong></h2><p>Sellas fell nearly 15% Wednesday and another 2.2% Thursday to $10.16 after its Phase 3 Regal leukemia trial reached the long-awaited 80th event, meaning 80 deaths.</p><p>The milestone triggers database lock, unblinding and final analysis, with preliminary topline results expected this quarter. “Reaching the 80th event represents a critical milestone in the Regal trial,” CEO Angelos Stergiou said.</p><p>Regal tests Galinpepimut-S (GPS) as maintenance treatment for patients in second complete remission. Results have not yet established whether GPS improved overall survival, the primary endpoint.&nbsp;</p><h2 class="st-heading-2"><strong>IBRX Slides Despite Approval And Trial Progress</strong></h2><p>ImmunityBio’s monthly decline comes despite the FDA’s recent expansion of Anktiva plus BCG’s approval to include BCG-unresponsive bladder cancer with papillary-only tumors, broadening its earlier indication involving carcinoma in situ.</p><p>The next catalyst is November’s readout from Quilt-2.005, a 366-patient trial comparing Anktiva plus BCG with BCG alone in patients who have not previously received BCG. ImmunityBio completed database lock last week and plans a fourth-quarter FDA submission, potentially moving treatment earlier in the disease course. CNBC’s Jim Cramer called ImmunityBio a “very good spec” earlier this week, citing biotech takeover activity.</p><h2 class="st-heading-2"><strong>How Do Retail Traders Feel About SLS, IBRX, IOVA?</strong></h2><p>On Stocktwits, IBRX led retail optimism with ‘extremely bullish’ sentiment and ‘extremely high’ message volume. SLS sentiment was ‘bullish’ amid ‘high’ message volume, while IOVA drew ‘bearish’ sentiment amid ‘low’ activity.&nbsp;</p><p>So far this year, IBRX has surged 341%, IOVA has gained 250% and SLS has climbed 169%, all outpacing XBI’s 30% advance.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rklb-stock-rocket-lab-nasa-robot-repairs-neutron-advances-100th-electron-ships/cZUh0nZR9RY">RKLB Stock Tests Bulls’ Patience — Rocket Lab’s NASA Robot Eyes Repairs As Neutron Advances, 100th Electron Ships&nbsp;</a></p>

Representative Image (Photo credit: Getty Images)

iShares Biotechnology ETF

ImmunityBio Inc

SELLAS Life Sciences Group Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

Investors are weighing the impact of a narrower, precision-medicine focused strategy in lung cancer clinical trials.

Speculation mounts regarding a potential acquisition of the company following recent share price volatility and interest from large pharma.

All eyes are on the upcoming earnings call to see if management can provide clarity on revenue guidance and trial timelines.

Disappointment over recent leadership communications has sparked significant debate about executive competence and strategic messaging.

Current Price	$8.48
Prev Close	$9.56
Open	$9.13
Dividend Yield	0.00%
50-Day Moving Average	$11.37
Beta	1.74
Avg. Volume	17.84M
PE Ratio	-11.76

52-Week High	$15.37
52-Week Low	$1.76
Market Capitalization	$3.84B
EPS (Annual)	-$1.09
Price to Book	5.22
Revenue Per Employee	$270,258.46

Feed

News

Sentiment

Earnings

Fundamentals

Info

IOVA Fundamentals